Evidence map›Paper›PMID 31108227›Full record

ArticleClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2020

Comparative Efficacy and Speed of Onset of Action of Infliximab vs Golimumab in Ulcerative Colitis.

Siddharth Singh, James A Proudfoot, Parambir S Dulai, Ronghui Xu, Brian G Feagan, William J Sandborn, Vipul Jairath

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Siddharth SinghDivision of Gastroenterology, UC San Diego School of Medicine, University of California, San Diego, La Jolla, California; Division of Biomedical Informatics, UC San Diego School of Medicine, University of California, San Diego, La Jolla, California. Electronic address: sis040@ucsd.edu.
James A ProudfootBiostatistics Unit, Altman Clinical and Translational Research Institute, UC San Diego School of Medicine, University of California, San Diego, La Jolla, California.
Parambir S DulaiDivision of Gastroenterology, UC San Diego School of Medicine, University of California, San Diego, La Jolla, California.
Ronghui XuBiostatistics Unit, Altman Clinical and Translational Research Institute, UC San Diego School of Medicine, University of California, San Diego, La Jolla, California; Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, California; Department of Mathematics, University of California, San Diego, La Jolla, California.
Brian G FeaganDivision of Epidemiology and Biostatistics, Western University, London, Ontario, Canada; Division of Gastroenterology, Department of Medicine, University Hospital, London Health Sciences Centre, Western University, London, Ontario, Canada.
William J SandbornDivision of Gastroenterology, UC San Diego School of Medicine, University of California, San Diego, La Jolla, California.
Vipul JairathDivision of Epidemiology and Biostatistics, Western University, London, Ontario, Canada; Division of Gastroenterology, Department of Medicine, University Hospital, London Health Sciences Centre, Western University, London, Ontario, Canada. Electronic address: vjairath@uwo.ca.
University of California San Diego · USWestern University · CA

Funding

UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
Comparative Risks and Benefits of Pharmacological Therapies for Older Patients with Inflammatory Bowel DiseasesK23DK117058 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SINGH, SIDDHARTH · 2018 to 2022
$971k
NCATS NIH HHS UL1 TR001442NIDDK NIH HHS K23 DK117058
6 · The paper itself

Abstract

BACKGROUND &

aimsWith several options available for patients with moderate-severe ulcerative colitis (UC), rapidity of symptom resolution could be an important differentiator. We compared the efficacy and speed of onset of action of infliximab vs golimumab induction therapy using patient-level data from phase 3 trials (ACT-1, ACT-2, and PURSUIT-SC).

methodsWe compared differences in proportions of patients who achieved the composite outcome of a rectal bleeding score=0 and stool frequency score ≤1 (patient-reported outcome 2 remission) at weeks 2 and 6 of treatment with standard-dose infliximab vs golimumab using logistic generalized estimating equation. Overall efficacy for inducing clinical remission (Mayo clinic score <3) was compared using logistic regression. Analyses were adjusted for sex, disease extent, baseline clinical and endoscopic severity, C-reactive protein, albumin, body weight and concomitant medications (immunomosuppressives, corticosteroids, and 5-aminsalicylates).

resultsTrial populations were similar and no differences were observed among the placebo groups in the studies. A significantly higher proportion patients treated with infliximab than golimumab achieved patient-reported outcome 2 remission at week 2 (35% vs 30%; adjusted odds ratio [OR], 1.71; 95% CI, 1.15-2.55) and at week 6 (50.0% vs 38.9%; adjusted OR, 2.0; 95% CI, 1.40-2.94). Infliximab-treated patients were also significantly more likely to achieve clinical remission than golimumab-treated patients (adjusted OR, 3.01; 95% CI, 1.95-4.70), with consistent findings in patients with moderate or severe UC.

conclusionsBased on a patient-level analysis of data from phase 3 trials, infliximab resolves symptoms more rapidly and has greater efficacy for inducing remission than golimumab in patients with moderate-to-severe UC.

Indexed as

Colitis, UlcerativeAntibodies, MonoclonalHumansInfliximabRemission InductionTreatment OutcomeTumor Necrosis Factor-alphaAntibodies, MonoclonalgolimumabInfliximabTumor Necrosis Factor-alphaComparative EfficacyInflammatory Bowel DiseasesOpen SciencePatient-Reported Outcomes

Identifiers

PMID31108227
PMCPMC6858937
OpenAlexW2946172582

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.